Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2008 1
2009 4
2010 5
2011 5
2012 2
2013 3
2014 4
2015 3
2016 2
2017 3
2018 4
2019 3
2020 8
2021 9
2022 6
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Among authors: chamuleau med. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: chamuleau med. Blood. 2023 Jun 22;141(25):3055-3064. doi: 10.1182/blood.2022018558. Blood. 2023. PMID: 37001036 Free PMC article.
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Among authors: chamuleau med. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.
Veltmaat N, Zhong Y, de Jesus FM, Tan GW, Bult JAA, Terpstra MM, Mutsaers PGNJ, Stevens WBC, Mous R, Vermaat JSP, Chamuleau MED, Noordzij W, Verschuuren EAM, Kok K, Kluiver JL, Diepstra A, Plattel WJ, van den Berg A, Nijland M. Veltmaat N, et al. Among authors: chamuleau med. J Hematol Oncol. 2023 Sep 14;16(1):104. doi: 10.1186/s13045-023-01500-x. J Hematol Oncol. 2023. PMID: 37705050 Free PMC article.
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P. Chamuleau MED, et al. Lancet Haematol. 2023 Dec;10(12):e966-e975. doi: 10.1016/S2352-3026(23)00279-X. Epub 2023 Oct 31. Lancet Haematol. 2023. PMID: 37922925 Clinical Trial.
Cyclosporin in cell therapy for cardiac regeneration.
Jansen Of Lorkeers SJ, Hart E, Tang XL, Chamuleau ME, Doevendans PA, Bolli R, Chamuleau SA. Jansen Of Lorkeers SJ, et al. J Cardiovasc Transl Res. 2014 Jul;7(5):475-82. doi: 10.1007/s12265-014-9570-8. Epub 2014 May 16. J Cardiovasc Transl Res. 2014. PMID: 24831573 Free PMC article. Review.
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
de Jonge AV, van Werkhoven E, Dinmohamed AG, Nijland M, Zwinderman AH, Bossuyt PM, Veldhuis MS, Rutten EGGM, Mous R, Vermaat JSP, Sandberg Y, de Jongh E, Bilgin YM, Boersma R, Koene H, Kersten MJ, de Jong D, Chamuleau MED. de Jonge AV, et al. Among authors: chamuleau med. Blood Cancer J. 2023 May 22;13(1):85. doi: 10.1038/s41408-023-00854-2. Blood Cancer J. 2023. PMID: 37217463 Free PMC article.
69 results